Medicine & Life Sciences
Olanzapine
78%
Mood Disorders
62%
Schizophrenia
52%
Meta-Analysis
48%
Bipolar Disorder
45%
Weight Gain
21%
Blood Glucose
19%
Parkinsonian Disorders
19%
Psychomotor Agitation
14%
Triglycerides
14%
Cholesterol
12%
Incidence
11%
Phenotype
10%
Bipolar and Related Disorders
10%
Psychiatry
8%
Cardiovascular Diseases
8%
Randomized Controlled Trials
7%
Tardive Dyskinesia
7%
low density lipoprotein triglyceride
6%
Sex Ratio
6%
Depressive Disorder
6%
Diabetes Complications
5%
Hypnotics and Sedatives
5%
Duration of Therapy
5%
Industry
5%
Metabolic Syndrome
5%
Antipsychotic Agents
5%
Information Storage and Retrieval
5%
LDL Cholesterol
5%
MEDLINE
5%
Life Style
4%
Mental Disorders
4%
PubMed
4%
Type 2 Diabetes Mellitus
4%
Smoking
4%
Diet
4%
Health Care Outcome Assessment
3%
Therapeutics
3%
Logistic Models
3%
Exercise
3%
Weights and Measures
3%
Databases
3%
Morbidity
3%
Mortality
2%
Chemical Compounds
Olanzapine
100%
Disorder
55%
Weight Gain
29%
Triglyceride
24%
Metabolic
23%
Cholesterol
21%
Glucose
17%
Antiparkinson Agent
9%
Antipsychotic
8%
Sedative Agent
8%
Low-Density Lipoprotein
6%
Dose
4%
Industry
4%
Weight
3%